Register for free
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

128.24 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Sep 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
36 37 Next >
Cullen Trims KVUE Stake With $149.5M Share Sale
Via The Motley Fool
Topics Regulatory Compliance
Healthcare Sector Navigates Turbulent Waters as Drug Pricing Agreements Reshape Market Landscape
September 30, 2025 – The healthcare sector today finds itself at a pivotal juncture, experiencing a complex mix of optimism and apprehension. While a landmark drug-pricing agreement between... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
Cullen Sells 1.4 Million Dow Shares Worth $39.7 Million Amid Steep Stock Decline
Via The Motley Fool
Topics Stocks
Monte Rosa Therapeutics Stock Scores Biggest Gain In Nearly A Year On $5.7B Novartis Deal For Immune-Mediated Diseases
Via Stocktwits
Google DeepMind Chief Eyes Radical AI-Powered Shift In Drug Discovery Speed — Eli Lilly, Novartis Are Already Onboard
Via Stocktwits
Pharma's Direct-To-Patient Wave Hits Novartis Next
The Pharmaceutical Research and Manufacturers of America (PhRMA) outlined initiatives to bolster U.S. manufacturing, ease patient costs, and improve access to medicine. 
Via Benzinga
AstraZeneca's Strategic Listing Harmonization: A Unified Global Platform for Growth
AstraZeneca (LSE: AZN, NASDAQ: AZN) has announced a significant strategic move to harmonize its stock market listings across the London Stock Exchange (LSE), Nasdaq Stockholm (STO), and the New York... 
Via MarketMinute
Topics Economy
Novartis AG-Sponsored ADR (NYSE:NVS): A Strong Dividend Stock with High Profitability and Sound Financial Health
Novartis (NVS) offers a strong 3.58% dividend yield with a history of steady payments, supported by high profitability and sound financial health for sustainable income. 
Via Chartmill
Major Insider Sale Casts Shadow on LENZ Therapeutics' Valuation
San Diego, CA – September 27, 2025 – LENZ Therapeutics (NASDAQ: LENZ) is facing heightened scrutiny this week following a significant insider share sale by a major shareholder, Versant Venture Capital... 
Via MarketMinute
Topics Artificial Intelligence
Why Is Avidity Biosciences Stock Down 20% Pre-market Today?
Via Stocktwits
Pharma Tariffs Back In Spotlight On New Trump Threat
President Donald Trump threatened 100% tariffs on some drug imports. 
Via Investor's Business Daily
Topics ETFs Government World Trade
Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet
Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de 
Via Benzinga
Topics Government World Trade
Trump's New Tariff Barrage Targets Drugs, Trucks, Cabinets: President Says Move Will Protect Manufacturers From 'Unfair Outside Competition'
President Donald Trump announced a barrage of new tariffs on Thursday, aimed at pharmaceuticals, heavy trucks and home furnishings in particular, to shore up domestic industry in these sectors, and... 
Via Benzinga
Topics Government World Trade
Eli Lilly Stock Is Trading Down Thursday: What's Behind The Move?
Eli Lilly and Company (NYSE: LLY) shares are trading lower after the company ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it... 
Via Benzinga
AI Takes Center Stage in Biodefense: DARPA's NODES Program Promises to Revolutionize Pandemic and Biowarfare Protection
In a groundbreaking leap for global health security, the Defense Advanced Research Projects Agency (DARPA) officially launched its Network of Optimal Dynamic Energy Signatures (NODES) program in July... 
Via MarketMinute
Topics Artificial Intelligence
Eli Lilly Ends Bimagrumab Obesity Study Weeks After Launch
On Wednesday, Eli Lilly & Co. (NYSE: LLY) ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began. 
Via Benzinga
Novartis, AbbVie Face Legal Defeat Over 340B Contract Pharmacies
A judge upholds Maine's contract pharmacy law, rejecting drugmakers' claims that it conflicts with federal rules governing the 340B drug discount program. 
Via Benzinga
Scholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection
FDA cites Catalent Indiana issues in Scholar Rock's SMA drug review; European approval decision expected in 2026, with Germany as the launch market. 
Via Benzinga
Roche Targets Top Spot In Weight Loss Drug Market
Roche advances weight loss drug CT-388 to Phase III, boosts pipeline with major acquisitions. 
Via Benzinga
Novartis Builds US Drug Reserves Against Potential Tariffs
Novartis bolsters U.S. drug reserves and plans $23 billion in investments as CEO Vas Narasimhan addresses tariff risks and trade policy uncertainty. 
Via Benzinga
Topics World Trade
Lilly's AI Gambit: TuneLab Poised to Reshape Biotech Drug Discovery Landscape
Eli Lilly and Company (NYSE: LLY) has unveiled its groundbreaking TuneLab Platform, an artificial intelligence (AI) and machine learning (ML) initiative designed to democratize advanced drug discovery... 
Via MarketMinute
Topics Animal Testing Artificial Intelligence Intellectual Property
Lilly's Oncology Momentum Soars: Olomorasib Gains Breakthrough Status, Jaypirca Achieves Landmark Clinical Successes
Eli Lilly and Company (NYSE: LLY) is making significant waves in the oncology landscape with a series of major announcements concerning two of its innovative cancer therapies: Olomorasib and Jaypirca... 
Via MarketMinute
Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments
Monte Rosa's stock jumps as it partners with Novartis to develop degraders for immune diseases, with up to $5.7 billion in payments. 
Via Benzinga
Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Compelling Case for Value Investors
Discover Novartis (NVS), an undervalued pharma stock with strong fundamentals, high profitability, and a solid margin of safety for value investors. 
Via Chartmill
This Applied Materials Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
 
Via Benzinga
Wall Street Cheers Nebius-Microsoft Megadeal While Apple Misses the Mark
U.S. markets closed higher on Tuesday, buoyed by fresh labor data signaling a cooling job market—potentially paving the way for Fed rate cuts. Nebius soared nearly 50% on a multibillion-dollar AI-cloud... 
Via Chartmill
Topics Economy
Trump's Biotech Playbook Ignites $350 Billion Investment Blitz
Trump's policies have sparked a $350B investment surge in US biotech, creating job & revenue opportunities. Investors can track with XBI or IBB ETFs and consider JNJ, NVS, LLY, AZN, BMY as potential... 
Via Benzinga
Topics ETFs Government
Why Novartis' $1.4 Billion Takeover Of Tourmaline Bio Just 'Makes Sense'
Novartis agreed to buy a cardiovascular-focused biotech company 
Via Investor's Business Daily
Novartis Snaps Up Cardio-Focused Tourmaline Bio For $1.4 Billion
Tourmaline Bio shares skyrocketed Tuesday after Novartis agreed to buy the cardiovascular-focused biotech company. 
Via Investor's Business Daily
Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver
Novartis is betting big on radioligand cancer therapy, but while the long-term growth story looks strong, NVS stock may face a short-term pullback 
Via MarketBeat
< Previous 1 2 3 4 5 6 7 8 9
...
36 37 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS